Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 20th Preview)
-
Earendil Labs raises $787M — AI platform scales drug pipeline
Earendil Labs announced a $787 million private financing to expand an AI-driven drug discovery platform that the company says has produced more than 40 programs. The funding positions Earendil to advance multiple preclinical candidates and to prepare for a potential public listing. Investors cited the firm’s high-throughput computational approach and early pipeline breadth as drivers of the large round. The round signals continued investor appetite for AI-native biotechs that promise to compress discovery timelines. Earendil’s platform reportedly integrates generative models and experimental feedback to progress multiple modalities in parallel. For readers: “foundation models” and other large AI systems are being repurposed to predict molecule properties and prioritize candidates across many targets. The company’s cash will accelerate IND-enabling studies and broaden discovery efforts, but execution risks remain around preclinical-to-clinic translation and regulatory scrutiny of AI-designed assets. The raise will also set valuation and comparables for other AI-biotech entrants heading toward late-stage private rounds or IPOs.
-
Verily raises $300M: Alphabet loses majority control
Verily secured $300 million in outside capital that ends Alphabet’s controlling stake in the healthcare innovation company, the firm announced. The financing—led by Series X Capital with other investors—repositions Verily as an independent growth-stage company with an expanded investor base and a new governance structure. Verily will use the proceeds to scale commercialization of digital health tools, diagnostics and clinical platforms. For industry readers: Verily’s pivot away from majority Alphabet ownership could accelerate commercial partnerships and licensing deals with life‑science partners that previously hesitated due to corporate parent dynamics. The deal reflects continued private investment appetite for health‑tech firms with differentiated data assets, but it raises questions about how Verily will balance product commercialization with long‑term research commitments previously underwritten by Alphabet.
-
Abbott closes $23B Exact Sciences buy — Diagnostics becomes core growth play
Abbott announced completion of its $23 billion acquisition of Exact Sciences after regulatory clearances, folding Cologuard, Oncotype DX and other cancer‑screening assays into Abbott’s diagnostics portfolio. Abbott said the deal will add roughly $3 billion in incremental sales in 2026 and accelerate its diagnostic growth strategy. Abbott framed the purchase as a strategic move to enter multi‑cancer early detection and expand its presence across oncology diagnostics. For readers: Cologuard is a stool‑based DNA methylation test for colorectal cancer screening, while Oncotype DX provides genomic risk stratification for breast cancer treatment decisions. Management cautioned on near‑term EPS dilution tied to financing, but emphasized long‑term revenue synergies as Abbott integrates Exact’s assay development and commercial channels into its global diagnostics footprint.
-
Novartis pays $2B upfront — Next‑gen PI3Kα joins breast cancer arsenal
Novartis agreed to pay $2 billion upfront to acquire an experimental, pan‑mutant‑selective PI3Kα inhibitor from Synnovation Therapeutics, aiming to bolster or defend its breast‑cancer franchise. The asset targets PIK3CA‑driven tumors and is positioned as a next‑generation option with reported improved selectivity over older PI3K inhibitors. Novartis executives characterized the deal as a strategic bolt‑on to compete against rivals developing agents in the same pathway. For readers: PI3Kα inhibitors target a common oncogenic node—PIK3CA mutations—that confer growth signals in many breast tumors. The transaction underscores Big Pharma’s continued appetite for buying targeted oncology assets late in discovery to refresh pipelines and mitigate competitive risk. The upfront price highlights the premium attached to selective PI3Kα chemistry and clinical differentiation potential.
-
Roche and Genentech abandon muscle‑building programs — Trials fail to show benefit
Roche confirmed it is halting development of emugrobart after a key study failed to show consistent improvements in muscle growth and motor function, notifying European patient communities. Separately, Genentech elected to stop a late‑stage RIPK1/RIPK1‑pathway program after interim analyses indicated the asset was unlikely to meet primary endpoints. Both decisions reflect near‑term clinical readouts that failed to deliver robust efficacy in rare neuromuscular indications and raise questions about mechanism translation from preclinical models to patients. For readers: spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD) require durable motor‑function gains—endpoints that are historically hard to shift. The program terminations will free resources but also leave gaps in therapeutic options and pipeline diversity for companies targeting muscle preservation. Investors and program teams will likely re‑evaluate biomarker strategies and patient selection to improve future trial signal detection.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.